IGI Logo

Aurobindo Pharma is currently trading at Rs. 1387.50, up by 1.40 points or 0.10% from its previous closing of Rs. 1386.10 on the BSE.

The scrip opened at Rs. 1392.80 and has touched a high and low of Rs. 1394.10 and Rs. 1380.85 respectively. So far 11343 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1394.10 on 17-Apr-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.

Last one week high and low of the scrip stood at Rs. 1394.10 and Rs. 1333.00 respectively. The current market cap of the company is Rs. 80441.02 crore.

The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.63% and 6.56% respectively.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Ravicti Oral Liquid 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC. The product will be manufactured by Unit-III of the company and will be launched immediately.

The approved product has an estimated market size of $50.2 million for the twelve months ending February 2026, according to IQVIA MAT. The company now has a total of 579 ANDA approvals (556 final approvals and 23 tentative approvals) from USFDA. Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.